Specialty Injectable Market, by Drug Type (Small Molecule Drugs and Biologics), by Application (Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Diseases, Auto-immune Disorders, and Others), by Distribution Channel (Hospital

Specialty Injectable Market, by Drug Type (Small Molecule Drugs and Biologics), by Application (Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Diseases, Auto-immune Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Specialty injectable is a high cost drug therapy that requires administration by injection. This medication is indicated for the treatment of chronic or life threatening diseases such as human immunodeficiency virus (HIV), rheumatoid arthritis, hemophilia, cancer, cardiovascular diseases, infectious diseases, auto immune disorders, and other diseases. Surveillance, counselling, or monitoring are all required when using specialty injectables. Specialty injectable are high cost drugs that require precise temperature control, special handling, and clinical management to ensure the drug performance.
Market Dynamics
Market players are indulged in receiving approvals for their products indicated for chronic or rare diseases from regulatory authorities. This is expected to drive the global specialty injectable market growth over the forecast period. For instance, on August 6, 2021, Sanofi, a pharmaceutical company that develops product for therapeutics treatments, received approval from the U.S. Food and Drug Administration (FDA) for Nexviazyme which is uses for pompe diseases, an inherited disordered disease where glycogen complex sugar is increased by using Nexviazyme, has received approval on the basis of positive results obtained from Phase 3 Clinical trial where Nexviazyme targets the M6P receptor which is clears the glycogen build up in muscle cells.

Market players are indulged in receiving approvals for their products by regulatory authorities is expected to drive the market growth over the forecast period. For instance, on December 23, 2021, Roche, a diagnostic and pharmaceutical company, announced the approval from European Commission for its Phesgo which is a combined dose of Perjeta and Herceptin used for the treatment of HER2 positive breast cancer. The approval was granted on the basis of results from pivotal phase 3 FeDeriCa trial which showed that Phesgo had delivered non inferior level of Perjeta and Herceptin in blood in comparison with IV formulation it showed safety and efficacy of Phesgo.

Key features of the study:
This report provides an in-depth analysis of global specialty injectable market, market size (US$ Billion), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global specialty injectable market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Pfizer Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Novartis AG, Baxter International Inc., Mylan N.V., Merck & Co. Inc., Fresenius SE & Co. KGaA, Endo International Plc., AstraZeneca, Hikma Pharmaceuticals PLC, Lupin Ltd., Genentech USA Inc., Sagent Pharmaceuticals Inc., Cipla Limited, Sun Pharmaceutical Industries Limited, Genzyme Corporation, Dr. Reddy's Laboratories, Biogen, Alnylam Pharmaceuticals Inc., and Amgen Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global specialty injectable market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the specialty Injectable market
Detailed Segmentation:
Global Specialty Injectable Market, By Drug Type:
Small Molecule Drugs
Biologics
Global Specialty Injectable Market, By Application:
Oncology
Cardiovascular Diseases
Central Nervous System Diseases
Infectious Diseases
Auto-immune Disorders
Others
Global Specialty Injectable Market, By Distribution Channel:
Hospital Pharmacies
Specialty Pharmacies
Online Pharmacies
Global Specialty Injectable Market, By Region:
North America
By Drug Type:
Small Molecule Drugs
Biologics
By Application:
Oncology
Cardiovascular Diseases
Central Nervous System Diseases
Infectious Diseases
Auto-immune Disorders
Others
By Distribution Channel:
Hospital Pharmacies
Specialty Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Drug Type:
Small Molecule Drugs
Biologics
By Application:
Oncology
Cardiovascular Diseases
Central Nervous System Diseases
Infectious Diseases
Auto-immune Disorders
Others
By Distribution Channel:
Hospital Pharmacies
Specialty Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Type:
Small Molecule Drugs
Biologics
By Application:
Oncology
Cardiovascular Diseases
Central Nervous System Diseases
Infectious Diseases
Auto-immune Disorders
Others
By Distribution Channel:
Hospital Pharmacies
Specialty Pharmacies
Online Pharmacies
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
Asia Pacific
By Drug Type:
Small Molecule Drugs
Biologics
By Application:
Oncology
Cardiovascular Diseases
Central Nervous System Diseases
Infectious Diseases
Auto-immune Disorders
Others
By Distribution Channel:
Hospital Pharmacies
Specialty Pharmacies
Online Pharmacies
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
Middle East
By Drug Type:
Small Molecule Drugs
Biologics
By Application:
Oncology
Cardiovascular Diseases
Central Nervous System Diseases
Infectious Diseases
Auto-immune Disorders
Others
By Distribution Channel:
Hospital Pharmacies
Specialty Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Type:
Small Molecule Drugs
Biologics
By Application:
Oncology
Cardiovascular Diseases
Central Nervous System Diseases
Infectious Diseases
Auto-immune Disorders
Others
By Distribution Channel:
Hospital Pharmacies
Specialty Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Pfizer Inc., *
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd.
Novartis AG,
Baxter International Inc.
Mylan N.V.,
Merck & Co. Inc.
Fresenius SE & Co. KGaA
Endo International Plc.
AstraZeneca
Hikma Pharmaceuticals Plc
Lupin Ltd.
Genentech USA Inc.
Sagent Pharmaceuticals Inc.
Cipla Limited
Sun Pharmaceutical Industries Limited
Genzyme Corporation
Dr. Reddy's Laboratories
Biogen
Alnylam Pharmaceuticals Inc.
Amgen Inc.
“*” marked represents similar segmentation in other categories in the respective section.